Literature DB >> 11914655

Evaluation of the blood coagulation mechanism and platelet aggregation in individuals with mechanical or biological heart prostheses.

C N Ferreira1, L M Vieira, L M S Dusse, C V Reis, C F S Amaral, W A M Esteves, L M A Fenelon, M G Carvalho.   

Abstract

Oral anticoagulants have been widely employed to decrease thrombotic risk by reducing the levels of vitamin K-dependent clotting factors. Paradoxically, the use of oral anticoagulants also decreases the levels of natural anticoagulants (protein C and protein S), which favors the hypercoagulability state. Increased platelet activation has been reported in patients undergoing warfarin treatment. These findings have raised questions about the antagonistic effect of oral anticoagulants and their implications for hemostatic balance. The aim of this study is to determine the relationship between warfarin dosage and prothrombin time [International Normalized Ratio (INR)], platelet aggregation, vitamin K-dependent clotting factors, and protein C and protein S. Blood samples from 27 patients were analyzed, seven with mechanical prostheses and 20 with biological prostheses, and 27 controls. Multiple regression analysis showed that factor II most significantly determines the INR. Results showed that the INR, clotting factors, and protein C and protein S activity did not correlate with warfarin dosage, highlighting the need for accurate laboratory monitoring of those undergoing anticoagulant therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11914655     DOI: 10.1097/00001721-200203000-00008

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  2 in total

1.  Evaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulation.

Authors:  Rolf Burghaus; Katrin Coboeken; Thomas Gaub; Lars Kuepfer; Anke Sensse; Hans-Ulrich Siegmund; Wolfgang Weiss; Wolfgang Mueck; Joerg Lippert
Journal:  PLoS One       Date:  2011-04-22       Impact factor: 3.240

2.  Computational investigation of potential dosing schedules for a switch of medication from warfarin to rivaroxaban-an oral, direct Factor Xa inhibitor.

Authors:  Rolf Burghaus; Katrin Coboeken; Thomas Gaub; Christoph Niederalt; Anke Sensse; Hans-Ulrich Siegmund; Wolfgang Weiss; Wolfgang Mueck; Takahiko Tanigawa; Jörg Lippert
Journal:  Front Physiol       Date:  2014-11-07       Impact factor: 4.566

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.